AstraZeneca announced the resumption of testing of its vaccine in the United States

The company reiterated that it expects to receive data on the vaccine’s effectiveness by the end of this year.

The United States is the latest country to resume phase three clinical trials of a new coronavirus vaccine developed by the University of Oxford in collaboration with the British-Swedish pharmaceutical company AstraZeneca. This is stated in a message distributed by the company on Friday evening.

“Clinical trials of the AstraZeneca and Oxford University AZD1222 vaccine have resumed worldwide after regulatory authorities in the US, UK, Brazil, South Africa, and Japan confirmed that it is safe,” the document says. – The food and drug administration (FDA) today allowed testing to begin again in the United States after it happened in other countries in recent weeks. The office examined the safety data of the drug obtained during trials in different countries of the world, and concluded that it is safe to resume them.”

The company reiterated that it expects to receive data on the vaccine’s effectiveness by the end of this year.

In early September, AstraZeneca suspended the third phase of testing its drug due to suspicions of a serious side effect in one of the patients. The media reported that a female volunteer from the UK who received the vaccine developed inflammation of the spinal cord (transverse myelitis), a rare but possible side effect when some vaccines are administered. AstraZeneca denied this information, pointing out that this diagnosis is not final, and pointed out that stopping tests and conducting the required checks in such cases is standard procedure. This was the second time that a British drug trial was suspended, and both times regulators concluded that there was a low probability of a link between the observed diseases and the vaccine or that there was insufficient data to conclude that there was or was not a link, after which the trials resumed.

or as guest:
Comments: 0